Evidence map›Paper›PMID 35590372›Full record

ArticleParticle and fibre toxicology2022

Two-year intermittent exposure of a multiwalled carbon nanotube by intratracheal instillation induces lung tumors and pleural mesotheliomas in F344 rats.

Motoki Hojo, Ai Maeno, Yoshimitsu Sakamoto, Aya Ohnuki, Yukie Tada, Yukio Yamamoto, Kiyomi Ikushima, Ryota Inaba, Jin Suzuki, Yuhji Taquahashi and 11 more

Open access · goldAbstract read
In one paragraph

Article in Particle and fibre toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Assessment of Pristine Carbon Nanotubes Toxicity in Rodent Models.International journal of molecular sciences · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Motoki Hojo *Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan. motoki_hojo@member.metro.tokyo.jp.
Ai Maeno *Department of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.
Yoshimitsu SakamotoDepartment of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.
Aya OhnukiDepartment of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.
Yukie TadaDepartment of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.
Yukio YamamotoDepartment of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.
Kiyomi IkushimaDepartment of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.
Ryota InabaDepartment of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.
Jin SuzukiDepartment of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.
Yuhji TaquahashiCenter for Biological Safety and Research, National Institute of Health Sciences, Kanagawa, Japan.
Satoshi YokotaCenter for Biological Safety and Research, National Institute of Health Sciences, Kanagawa, Japan.
Norihiro KobayashiCenter for Biological Safety and Research, National Institute of Health Sciences, Kanagawa, Japan.
Makoto OhnishiJapan Bioassay Research Center, Japan Organization of Occupational Health and Safety, Kanagawa, Japan.
Yuko GotoJapan Bioassay Research Center, Japan Organization of Occupational Health and Safety, Kanagawa, Japan.
Takamasa NumanoDIMS Institute of Medical Science, Aichi, Japan.
Hiroyuki TsudaNanotoxicology Project, Nagoya City University, Aichi, Japan.
David B AlexanderNanotoxicology Project, Nagoya City University, Aichi, Japan.
Jun KannoCenter for Biological Safety and Research, National Institute of Health Sciences, Kanagawa, Japan.
Akihiko HiroseCenter for Biological Safety and Research, National Institute of Health Sciences, Kanagawa, Japan.
Akiko InomataDepartment of Pharmaceutical and Environmental Sciences, Tokyo Metropolitan Institute of Public Health, 3-24-1 Hyakunincho, Shinjuku, Tokyo, 169-0073, Japan.
Dai NakaeAnimal Medical Course, Department of Medical Sports, Faculty of Health Care and Medical Sports, Teikyo Heisei University, 4-1 Uruido-Minami, Ichihara, Chiba, 290-0193, Japan. d.nakae@thu.ac.jp.
Tokyo Metropolitan Institute of Public Health · JPNational Institute of Health Sciences · JPJapan Organization of Occupational Health and Safety · JPNagoya City University · JPTeikyo Heisei University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA mounting number of studies have been documenting the carcinogenic potential of multiwalled carbon nanotubes (MWCNTs); however, only a few studies have evaluated the pulmonary carcinogenicity of MWCNTs in vivo. A 2-year inhalation study demonstrated that MWNT-7, a widely used MWCNT, was a pulmonary carcinogen in rats. In another 2-year study, rats administered MWNT-7 by intratracheal instillation at the beginning of the experimental period developed pleural mesotheliomas but not lung tumors. To obtain data more comparable with rats exposed to MWNT-7 by inhalation, we administered MWNT-7 to F344 rats by intratracheal instillation once every 4-weeks over the course of 2 years at 0, 0.125, and 0.5 mg/kg body weight, allowing lung burdens of MWNT-7 to increase over the entire experimental period, similar to the inhalation study.

resultsAbsolute and relative lung weights were significantly elevated in both MWNT-7-treated groups. Dose- and time-dependent toxic effects in the lung and pleura, such as inflammatory, fibrotic, and hyperplastic lesions, were found in both treated groups. The incidences of lung carcinomas, lung adenomas, and pleural mesotheliomas were significantly increased in the high-dose group compared with the control group. The pleural mesotheliomas developed mainly at the mediastinum. No MWNT-7-related neoplastic lesions were noted in the other organs. Cytological and biochemical parameters of the bronchoalveolar lavage fluid (BALF) were elevated in both treated groups. The lung burden of MWNT-7 was dose- and time-dependent, and at the terminal necropsy, the average value was 0.9 and 3.6 mg/lung in the low-dose and high-dose groups, respectively. The number of fibers in the pleural cavity was also dose- and time-dependent.

conclusionsRepeated administration of MWNT-7 by intratracheal instillation over the 2 years indicates that MWNT-7 is carcinogenic to both the lung and pleura of rats, which differs from the results of the 2 carcinogenicity tests by inhalation or intratracheal instillation.

Indexed as

Lung NeoplasmsMesotheliomaMesothelioma, MalignantNanotubes, CarbonAnimalsCarcinogensRatsRats, Inbred F344CarcinogensNanotubes, CarbonCarcinogenicityIntratracheal instillationLung burdenLung tumorsMWCNTPleural mesothelioma

Identifiers

PMID35590372
PMCPMC9118836
OpenAlexW4280598759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.